Turn Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company focused on developing localized, non-systemic therapies for inflammatory skin diseases, advanced wound care, and infectious diseases. The company's proprietary PermaFusion® platform technology enhances drug performance by enabling the stable suspension of water-soluble active pharmaceutical ingredients in oil-based carriers without emulsifiers, improving bioavailability and reducing required dosages. Its lead investigational therapy, GX-03, is a potentially first-in-class, non-systemic topical inhibitor targeting IL-36 and IL-31 pathways, currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema). Turn Therapeutics also holds three FDA clearances for its proprietary wound and dermatology formulations (including Hexagen) and is pursuing global health initiatives in thermostable vaccine delivery.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of lead candidate GX-03, a first-in-class, non-systemic topical inhibitor targeting IL-36 and IL-31 pathways for moderate-to-severe atopic dermatitis and onychomycosis.
Expected impact: Establishment of a highly differentiated, localized treatment option for inflammatory skin diseases with minimal systemic side effects.
Expanding the pipeline to include a thermostable intranasal influenza vaccine candidate that leverages the proprietary PermaFusion delivery technology to stimulate systemic immunity without adjuvants.
Expected impact: Broadens the addressable market into infectious diseases and pandemic-ready vaccine delivery systems.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Combines Turn's proprietary PermaFusion delivery platform with Medline's global scale and distribution capabilities to commercialize professional and retail wound care products.
Terms: Specific financial terms, product categories, and development timelines remain confidential, but the partnership is expected to generate near-term revenue for Turn starting in late 2026.